The Finnish national guideline for diagnosis, treatment and follow‐up of patients with wet age‐related macular degeneration

Age‐related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti‐VEGF treatment have revolutionized the prognosis of the wet form of AMD...

Full description

Saved in:
Bibliographic Details
Published in:Acta ophthalmologica (Oxford, England) England), 2017-07, Vol.95 (A105 Suppl), p.1-9
Main Authors: Tuuminen, Raimo, Uusitalo‐Järvinen, Hannele, Aaltonen, Vesa, Hautala, Nina, Kaipiainen, Sulevi, Laitamäki, Nina, Ollila, Marko, Rantanen, Jari, Välimäki, Satu, Sipilä, Raija, Laukkala, Tanja, Komulainen, Jorma, Tommila, Petri, Immonen, Ilkka, Tuulonen, Anja, Kaarniranta, Kai
Format: Article
Language:English
Subjects:
Age
Aged
Aged, 80 and over
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Bevacizumab - adverse effects
Bevacizumab - therapeutic use
Developed countries
Diagnosis
Diagnostic Techniques, Ophthalmological
Eye
Female
Finland
Follow-Up Studies
Humans
Incidence
Intravitreal Injections
Laser Coagulation
Macular degeneration
Male
Patients
Photochemotherapy
Ranibizumab - adverse effects
Ranibizumab - therapeutic use
Receptors, Vascular Endothelial Growth Factor - therapeutic use
Recombinant Fusion Proteins - adverse effects
Recombinant Fusion Proteins - therapeutic use
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Visual Acuity - physiology
Wet Macular Degeneration - diagnosis
Wet Macular Degeneration - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Age‐related macular degeneration (AMD) is the main cause of visual impairment in developed countries. Several improvements in the visualization of posterior segment of the eye together with the introduction of intravitreal anti‐VEGF treatment have revolutionized the prognosis of the wet form of AMD (wAMD). Increasing incidence of wAMD together with the limited resources of society and of the healthcare system poses challenges for the provision and development of care. In context of these current aspects, we aimed to set evidence‐based medical guidelines for diagnosis, treatment and follow‐up of patients with wAMD.
ISSN:1755-375X
1755-3768
DOI:10.1111/aos.13501